NCT03478891View on ClinicalTrials.gov

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions

Healthy Adult Immune Responses to Vaccine

Interventions

BIOLOGICAL

VRC-EBOMAB092-00-AB (MAb114)

VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03478891 - Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults | Biotech Hunter | Biotech Hunter